Press Releases

VAXIL BIO LTD. an innovative biotech company announces that further to our press release from October 14, 2021, the Company, together with Short Wave Pharma Inc , have agreed not to pursue Vaxil's acquisition of Shortwave. The decision was reached by both entities following a due diligence process, concluding that the transaction does not deliver sufficient synergies for the two parties. The parties believe that value can be created by meeting the medical needs of patients

EKF Diagnostics, the global in vitro diagnostics company, announces that it has acquired Advanced Diagnostic Laboratory LLC (“ADL Health”), a Texas based PCR-focused testing laboratory certified under the Clinical Laboratory Improvement Amendments (“CLIA”) for high-complexity molecular diagnostics testing. ADL Health’s CLIA-certified laboratory covers the fields of clinical, forensic and microbiological tests. The business has ISO 15189 Medical Laboratory accredi

Olympus Corporation, a global leader in medical technology, has announced the establishment of Olympus Innovation Ventures to invest in pioneering startups with innovative technologies that improve clinical outcomes, reduce healthcare costs and enhance the quality of life for patients. Olympus Innovation Ventures, a fully-owned subsidiary of Olympus Corporation of the Americas, is a venture capital fund focused on startups poised to improve patient outcomes, radically advance the de

Virpax Pharmaceuticals, Inc. a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, today announced that the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) has awarded research and development contracts to support Good Manufacturing Practices (GMP) production of drug substance and drug product. as well as to support Good Laboratory Practices (GLP) toxicology, safety st

MEI Pharma, Inc. a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced that the U.S. Food and Drug Administration (FDA) granted orphan-drug designation (ODD) to zandelisib for the treatment of follicular lymphoma. Orphan-drug de

CPhI Worldwide announces the winners of the 18th edition of the CPhI Pharma Awards, hosted live in Milan, with winners spanning some 10 distinct categories. The Awards seek to recognise ‘Excellence in Pharma’ , assessing entries from the industry leading companies and individuals. The prestigious Excellence in Pharma: CEO of the Year Award was handed to Lynne Ann du Toit from Eurolab for her clear vision on what the future of cancer treatment in South Af

Roquette, a global leader in plant-based ingredients, pioneer of plant proteins and world-leading provider of pharmaceutical excipients, has today announced the launch of its ready-to-use, pharmaceutical grade solution for vegetarian softgel capsule formulation – LYCAGEL® Premix. Developed based on Roquette’s market-first pea starch technology – LYCAGEL® – launched in 2020, the new softgel blend provides manufacturers with an easy-to-use and convenient solution

LexaGene Holdings, Inc. a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced it has successfully expanded its bio-pharmaceutical (“bio-pharma”) contamination panel by developing a Burkholderia1 test for use on its MiQLab™ System. Burkholderia cepacia complex, a group of about 24 related environmental bacteria, is a problem contaminant for the bio-pharma industry. B. cepacia is the most common mic

CPhI opens its doors to international pharma for the first time in two years as industry confidence surges to record highs according to executives in the CPhI Annual Survey. The survey insights are published as part of the CPhI Annual Report – which is launched each year at CPhI Worldwide  and compile the thoughts of over 370 executives from more than 30 countries. The CPhI Pharma Index, a composite average of the main small molecule categories[1]  surged by 3.5% in

Ferrer, an international pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has today announced the next major milestone in its mission to develop transformative therapies for Amyotrophic Lateral Sclerosis (ALS) – marked by the first patient enrolled in the ALS Deceleration with ORal Edaravone (ADORE), FNP122 Phase III clinical trial. The trial will enrol about 300 patients across European countries and it will evaluate the ef